RECURSION PHARMACEUTICALS-A (RXRX)
US75629V1044 - Common Stock
3 Millionaire-Maker Biotech Stocks
The risk at these companies is above average, and they're sure to remain volatile. This volatility, however, includes explosively bullish potential.
AI in Healthcare: Unveiling the Future with a 42.20% CAGR Through 2029
/PRNewswire/ -- Across several sectors the use of artificial intelligence (AI) is making a huge impact, with healthcare emerging as possibly receiving the...
Where Will Recursion Pharmaceuticals Be in 5 Years?
A lot is riding on whether its platform is valuable, or vaporware.
Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer
Dr. Khan, formerly the Chief Data Science Officer and Global Head of Strategy and Portfolio, Innovative Medicine R&D at Johnson & Johnson (J&J), will also join Recursion’s Board of Directors
Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer
Dr. Khan, formerly the Chief Data Science Officer and Global Head of Strategy and Portfolio, Innovative Medicine R&D at Johnson & Johnson (J&J), will also...
Biotech on a Budget: 7 Stocks Under $10 With Huge Potential
With the medical care industry always liable for negative surprises, you might as well go for big upside with under-$10 biotech stocks.
Wall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for April 2024
Through opportunity for growth and strong financial performance, these three Cathie Wood stocks could provide generous returns.
Can Recursion Pharmaceuticals Stock Double in 5 Years? Here's What It Would Take.
Recursion is playing the long game with its AI-focused approach to drug discovery and development.
The AI Advantage: 2 Healthcare Stocks at the Forefront of Innovation
They might not be profitable yet, but they're swinging for the fences.
Is This Under-the-Radar Artificial Intelligence (AI) Stock a Buy?
This stock's upside is huge, but so is its downside.
Recursion Pharmaceuticals Breaks Below 200-Day Moving Average - Notable for RXRX
Recursion to Participate in Upcoming Investor Conference
Recursion Publishes Annual Environmental, Social and Governance Report
Provides progress updates in support of long-term commitments focused on reducing greenhouse gas emissions, improving workforce diversity and accelerating community impact.
Recursion Publishes Annual Environmental, Social and Governance Report
Provides progress updates in support of long-term commitments focused on reducing greenhouse gas emissions, improving workforce diversity and accelerating...
Recursion Announces Plans to Open New Office in London
Appoints Michael Bronstein as Scientific Advisor and launches recruiting effort to fill the first 20 open roles across technology and biology, establishing a hub for world-class TechBio talent in the heart of King’s Cross neighborhood
Recursion Announces Plans to Open New Office in London
Appoints Michael Bronstein as Scientific Advisor and launches recruiting effort to fill the first 20 open roles across technology and biology, establishing...
Recursion Pharmaceuticals Stock Has 33% Upside, According to 1 Wall Street Analyst
The company just made a provocative move in one of its collaborations.
The Top 7 Small-Cap Stocks to Buy in March 2024
These top small-cap stocks to buy are set for a strong 2024 as reduced inflation increases their growth prospects.
The Top 3 Healthcare Stocks to Buy on Weakness in 2024
Many healthcare stocks have extremely bright outlooks and very low valuations. Here are three top healthcare stocks to buy.
Recursion Hosts Second Annual Rare Disease Day Events for Utah’s Rare Disease Community
Recursion Hosts Second Annual Rare Disease Day Events for Utah’s Rare Disease Community
SALT LAKE CITY, March 01, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize...
Cathie Wood Just Bought These 3 Biotech Stocks. Should You Buy, Too?
On the leading edge of rare disease treatment and therapy is where you will find these Cathie Wood biotech stocks.
Recursion to Participate in Upcoming Investor Conferences
Recursion to Participate in Upcoming Investor Conferences
SALT LAKE CITY, March 01, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize...